semaglutide and cardiovascular outcomes in obesity align more closely with attained dose than achieved weight loss Semaglutide and Cardiovascular Health |

[DOI] [PMC free article] [PubMed] [Google Scholar] 11.Aroda V.R., Bauer R., Christiansen E., Haluzk M., Kallenbach K., Montanya E., Rosenstock J., Meier J.J

GLP1-RA have demonstrated effectiveness in lowering glycated hemoglobin (HbA1C), decreasing weight, and reducing the risk of major cardiovascular events in patients with T2DM

Yet, disappointingly, when anti-inflammatory agents were used for a primary diagnosis of depression, most studies failed to show significant effects in the primary outcome analysis [196,197,198]

However, these are subjective experiences and individual reactions can vary greatly

bit.ly/JASN0477 @LParkerGregg1 @MichaelEMatheny Little is known about the association of discontinuation of sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RA) with outcomes in patients with CKD

What foods should be avoided while taking Saxenda (liraglutide)